Insider Trades75 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 1, 2026 | Sell | BMY | Cari Gallman | EVP, General Counsel | 543 | $65.31 | $130.0B | -7.28% | +49.67% | $35.5K | -3.83% | — | Buy Now |
| Aug 1, 2026 | Sell | BMY | Cristian Massacesi | EVP,Chief Med Offr,Head of Dev | 26,175 | $65.31 | $130.0B | -7.28% | +49.67% | $1.7M | -12.79% | — | Buy Now |
| Jun 3, 2026 | Sell | BMY | Bartie Wendy Short | EVP, Corporate Affairs | 3,876 | $54.72 | $130.0B | -7.28% | +49.67% | $212.1K | -16.15% | — | Buy Now |
| May 1, 2026 | Sell | BMY | Adam Lenkowsky | EVP, Chief Commercial Officer | 599 | $58.22 | $130.0B | -7.28% | +49.67% | $34.9K | -2.76% | — | Buy Now |
| Apr 1, 2026 | Sell | BMY | Karin Shanahan | EVP, Chief Supply Chain & Ops | 1,692 | $61.73 | $130.0B | -7.28% | +49.67% | $104.4K | -6.13% | — | Buy Now |
| Apr 1, 2026 | Sell | BMY | David V Elkins | EVP, Chief Financial Officer | 30,000 | $61.67 | $130.0B | -7.28% | +49.67% | $1.9M | -8.50% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | Bartie Wendy Short | EVP, Corporate Affairs | 1,275 | $60.13 | $130.0B | -7.28% | +49.67% | $76.7K | -3.29% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | Phil M Holzer | SVP and Controller | 1,358 | $60.13 | $130.0B | -7.28% | +49.67% | $81.7K | -2.14% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | Lynelle Hoch | President, Cell Therapy Org. | 1,391 | $60.13 | $130.0B | -7.28% | +49.67% | $83.6K | -3.65% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | Ahn Amanda Poole | EVP, Chief People Officer | 1,992 | $60.13 | $130.0B | -7.28% | +49.67% | $119.8K | -3.34% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | Cari Gallman | EVP, General Counsel | 2,165 | $60.13 | $130.0B | -7.28% | +49.67% | $130.2K | -2.07% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | Robert M Plenge | EVP, Chief Research Officer | 4,535 | $60.13 | $130.0B | -7.28% | +49.67% | $272.7K | -4.23% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 6,582 | $60.13 | $130.0B | -7.28% | +49.67% | $395.8K | -4.30% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | Adam Lenkowsky | EVP, Chief Commercial Officer | 7,015 | $60.13 | $130.0B | -7.28% | +49.67% | $421.8K | -4.55% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | Karin Shanahan | EVP, Chief Supply Chain & Ops | 7,760 | $60.13 | $130.0B | -7.28% | +49.67% | $466.6K | -6.17% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | David V Elkins | EVP, Chief Financial Officer | 16,114 | $60.13 | $130.0B | -7.28% | +49.67% | $968.9K | -2.49% | — | Buy Now |
| Mar 10, 2026 | Sell | BMY | Christopher S. Boerner | Chief Executive Officer | 21,229 | $60.13 | $130.0B | -7.28% | +49.67% | $1.3M | -6.27% | — | Buy Now |
| Feb 27, 2026 | Sell | BMY | Benjamin Hickey | President, RayzeBio Org. | 1,672 | $62.37 | $130.0B | -7.28% | +49.67% | $104.3K | -7.73% | — | Buy Now |
| Feb 1, 2026 | Sell | BMY | Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 833 | $55.05 | $130.0B | -7.28% | +49.67% | $45.9K | -3.74% | — | Buy Now |
| Feb 1, 2026 | Sell | BMY | Benjamin Hickey | President, RayzeBio Org. | 3,810 | $55.05 | $130.0B | -7.28% | +49.67% | $209.7K | -13.16% | — | Buy Now |
| Nov 1, 2025 | Sell | BMY | Christopher S. Boerner | Chief Executive Officer | 1,238 | $46.07 | $130.0B | -7.28% | +49.67% | $57.0K | -14.83% | — | Buy Now |
| Nov 1, 2025 | Sell | BMY | Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 2,665 | $46.07 | $130.0B | -7.28% | +49.67% | $122.8K | -7.63% | — | Buy Now |
| Nov 1, 2025 | Sell | BMY | Karin Shanahan | EVP, Chief Supply Chain & Ops | 3,213 | $46.07 | $130.0B | -7.28% | +49.67% | $148.0K | -9.84% | — | Buy Now |
| Oct 2, 2025 | Sell | BMY | Cari Gallman | EVP, General Counsel | 2,332 | $45.73 | $130.0B | -7.28% | +49.67% | $106.6K | -12.99% | — | Buy Now |
| Sep 2, 2025 | Sell | BMY | David V Elkins | EVP, Chief Financial Officer | 56,000 | $47.33 | $130.0B | -7.28% | +49.67% | $2.7M | -25.07% | — | Buy Now |
| Sep 1, 2025 | Sell | BMY | Bartie Wendy Short | EVP, Corporate Affairs | 632 | $47.18 | $130.0B | -7.28% | +49.67% | $29.8K | -8.39% | — | Buy Now |
| Aug 2, 2025 | Sell | BMY | Bartie Wendy Short | EVP, Corporate Affairs | 378 | $44.23 | $130.0B | -7.28% | +49.67% | $16.7K | -6.94% | — | Buy Now |
| Aug 1, 2025 | Sell | BMY | Cari Gallman | EVP, General Counsel | 543 | $44.23 | $130.0B | -7.28% | +49.67% | $24.0K | -5.20% | — | Buy Now |
| Jun 13, 2025 | Sell | BMY | Christopher S. Boerner | Chief Executive Officer | 125,438 | $49.75 | $130.0B | -7.28% | +49.67% | $6.2M | +0.00% | — | Buy Now |
| Jun 3, 2025 | Sell | BMY | Bartie Wendy Short | EVP, Corporate Affairs | 3,334 | $48.09 | $130.0B | -7.28% | +49.67% | $160.3K | -13.82% | — | Buy Now |
| Jun 3, 2025 | Sell | BMY | Christopher S. Boerner | Chief Executive Officer | 125,440 | $48.09 | $130.0B | -7.28% | +49.67% | $6.0M | +0.00% | — | Buy Now |
| May 9, 2025 | Sell | BMY | Benjamin Hickey | President, RayzeBio Org. | 97.391 | $38.01 | $130.0B | -7.28% | +49.67% | $3.7K | -100.00% | — | Buy Now |
| Apr 25, 2025 | Buy | BMY | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 4,250 | $47.58 | $130.0B | -7.28% | +49.67% | $202.2K | +5.36% | — | Buy Now |
| Apr 1, 2025 | Sell | BMY | Karin Shanahan | EVP, Glob. Prod. Dev. & Supply | 1,692 | $59.55 | $130.0B | -7.28% | +49.67% | $100.8K | -9.00% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Phil M Holzer | SVP and Controller | 1,820 | $63.11 | $130.0B | -7.28% | +49.67% | $114.9K | -2.63% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Cari Gallman | EVP, Corporate Affairs | 1,940 | $63.11 | $130.0B | -7.28% | +49.67% | $122.4K | -3.06% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Lynelle Hoch | President, Cell Therapy Org. | 2,248 | $63.11 | $130.0B | -7.28% | +49.67% | $141.9K | -7.55% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Ahn Amanda Poole | EVP, Chief People Officer | 2,273 | $63.11 | $130.0B | -7.28% | +49.67% | $143.4K | -3.85% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Robert M Plenge | EVP, Chief Research Officer | 3,610 | $63.11 | $130.0B | -7.28% | +49.67% | $227.8K | -2.97% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Adam Lenkowsky | EVP, Chief Commercial Officer | 6,065 | $63.11 | $130.0B | -7.28% | +49.67% | $382.8K | -4.74% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 6,711 | $63.11 | $130.0B | -7.28% | +49.67% | $423.5K | -5.88% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Karin Shanahan | EVP, Glob. Prod. Dev. & Supply | 7,173 | $63.11 | $130.0B | -7.28% | +49.67% | $452.7K | -7.75% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 16,056 | $63.11 | $130.0B | -7.28% | +49.67% | $1.0M | -3.97% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Sandra Leung | EVP, General Counsel | 17,710 | $63.11 | $130.0B | -7.28% | +49.67% | $1.1M | -1.17% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | David V Elkins | EVP, Chief Financial Officer | 20,935 | $63.11 | $130.0B | -7.28% | +49.67% | $1.3M | -2.16% | — | Buy Now |
| Mar 10, 2025 | Sell | BMY | Christopher S. Boerner | Chief Executive Officer | 21,797 | $63.11 | $130.0B | -7.28% | +49.67% | $1.4M | -2.94% | — | Buy Now |
| Mar 1, 2025 | Sell | BMY | Benjamin Hickey | President, RayzeBio Org. | 1,630 | $59.62 | $130.0B | -7.28% | +49.67% | $97.2K | -9.59% | — | Buy Now |
| Feb 20, 2025 | Buy | BMY | Christopher S. Boerner | Chief Executive Officer | 2,000 | $55.05 | $130.0B | -7.28% | +49.67% | $110.1K | +1.95% | — | Buy Now |
| Feb 14, 2025 | Buy | BMY | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 1,823.486 | $54.84 | $130.0B | -7.28% | +49.67% | $100.0K | +2.94% | — | Buy Now |
| Feb 1, 2025 | Sell | BMY | Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 833 | $58.95 | $130.0B | -7.28% | +49.67% | $49.1K | -8.03% | — | Buy Now |
| Feb 1, 2025 | Sell | BMY | Benjamin Hickey | President, RayzeBio Org. | 3,725 | $58.95 | $130.0B | -7.28% | +49.67% | $219.6K | -12.01% | — | Buy Now |
| Nov 4, 2024 | Sell | BMY | Phil M Holzer | SVP and Controller | 700 | $55.62 | $130.0B | -7.28% | +49.67% | $38.9K | -5.62% | — | Buy Now |
| Nov 1, 2024 | Sell | BMY | Christopher S. Boerner | Chief Executive Officer | 1,488 | $54.32 | $130.0B | -7.28% | +49.67% | $80.8K | -1.32% | — | Buy Now |
| Nov 1, 2024 | Buy | BMY | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 1,830 | $54.67 | $130.0B | -7.28% | +49.67% | $100.1K | +3.04% | — | Buy Now |
| Oct 2, 2024 | Sell | BMY | Cari Gallman | EVP, Corporate Affairs | 1,648 | $53.76 | $130.0B | -7.28% | +49.67% | $88.6K | -10.44% | — | Buy Now |
| Aug 1, 2024 | Sell | BMY | Cari Gallman | EVP, Corporate Affairs | 384 | $48.17 | $130.0B | -7.28% | +49.67% | $18.5K | -8.32% | — | Buy Now |
| Apr 1, 2024 | Sell | BMY | Karin Shanahan | EVP, Glob. Prod. Dev. & Supply | 1,196 | $52.99 | $130.0B | -7.28% | +49.67% | $63.4K | -9.10% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | Cari Gallman | EVP, Corporate Affairs | 696 | $53.79 | $130.0B | -7.28% | +49.67% | $37.4K | -2.65% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | Lynelle Hoch | President, Cell Therapy Org. | 1,308 | $53.79 | $130.0B | -7.28% | +49.67% | $70.4K | -6.01% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | Ahn Amanda Poole | EVP, Chief Human Resources | 1,375 | $53.79 | $130.0B | -7.28% | +49.67% | $74.0K | -3.61% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | Phil M Holzer | SVP and Controller | 1,389 | $53.79 | $130.0B | -7.28% | +49.67% | $74.7K | -2.68% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | Robert M Plenge | EVP, Chief Research Officer | 1,965 | $53.79 | $130.0B | -7.28% | +49.67% | $105.7K | -2.52% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | Adam Lenkowsky | EVP, Chief Commercial Officer | 4,323 | $53.79 | $130.0B | -7.28% | +49.67% | $232.5K | -5.50% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | Samit Hirawat | EVP,Chief Med.Offr.,Drug Dev. | 13,649 | $53.79 | $130.0B | -7.28% | +49.67% | $734.2K | -4.44% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | Sandra Leung | EVP, General Counsel | 16,660 | $53.79 | $130.0B | -7.28% | +49.67% | $896.1K | -1.46% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | David V Elkins | EVP, Chief Financial Officer | 18,522 | $53.79 | $130.0B | -7.28% | +49.67% | $996.3K | -2.59% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | Christopher S. Boerner | Chief Executive Officer | 19,407 | $53.79 | $130.0B | -7.28% | +49.67% | $1.0M | -3.34% | — | Buy Now |
| Mar 10, 2024 | Sell | BMY | Giovanni Caforio | Executive Chair of the Board | 67,823 | $53.79 | $130.0B | -7.28% | +49.67% | $3.6M | -4.84% | — | Buy Now |
| Feb 1, 2024 | Sell | BMY | Gregory Scott Meyers | EVP, Chief Digital & Tech Off. | 754 | $48.67 | $130.0B | -7.28% | +49.67% | $36.7K | -6.78% | — | Buy Now |
| Dec 5, 2023 | Buy | BMY | Christopher S. Boerner | Chief Executive Officer | 2,000 | $49.78 | $130.0B | -7.28% | +49.67% | $99.6K | +2.48% | — | Buy Now |
| Dec 2, 2023 | Sell | BMY | Robert M Plenge | EVP, Chief Research Officer | 274 | $50.10 | $130.0B | -7.28% | +49.67% | $13.7K | -3.81% | — | Buy Now |
| Dec 2, 2023 | Sell | BMY | Christopher S. Boerner | Chief Executive Officer | 1,350 | $50.10 | $130.0B | -7.28% | +49.67% | $67.6K | -1.65% | — | Buy Now |
| Dec 2, 2023 | Sell | BMY | David V Elkins | EVP, Chief Financial Officer | 3,730 | $50.10 | $130.0B | -7.28% | +49.67% | $186.9K | -2.16% | — | Buy Now |
| Nov 28, 2023 | Buy | BMY | Christopher S. Boerner | Chief Executive Officer | 3,071 | $48.86 | $130.0B | -7.28% | +49.67% | $150.0K | +4.02% | — | Buy Now |
| Oct 10, 2023 | Sell | BMY | Giovanni Caforio | Board Chair and CEO | 440 | $56.39 | $130.0B | -7.28% | +49.67% | $24.8K | -0.12% | — | Buy Now |